Stereotactic Body Radiation for Prostate Oligometastases
Status:
Active, not recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Men with oligometastatic prostate cancer lesions will be randomized (1:2) to observation
versus SBRT. The study will NOT be blinded. Within three weeks of the initial treatment
planning, SBRT (1-5 fractions) will be administered.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins